Evaxion Biotech A/S - Expects Existing Cash and Cash Equivalents Will Be Sufficient to Fund Its Oper Expenses and Capex Requirements Into Q1 2025
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.